Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) saw a significant increase in short interest in October. As of October 30th, there was short interest totaling 152,917 shares, an increase of 69.8% from the October 15th total of 90,040 shares. Currently, 6.8% of the shares of the company are sold short. Based on an average trading volume of 6,760,367 shares, the short-interest ratio is currently 0.0 days.
Lakewood-Amedex Biotherapeutics Price Performance
Shares of LABT stock traded down $0.06 during trading hours on Monday, hitting $0.22. 789,942 shares of the company were exchanged, compared to its average volume of 7,484,873. The company’s fifty day moving average price is $0.99. Lakewood-Amedex Biotherapeutics has a 52-week low of $0.17 and a 52-week high of $98.20. The firm has a market cap of $519,978.00 and a PE ratio of -0.05.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($2.75) EPS for the quarter. Research analysts forecast that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
LABT has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Lakewood-Amedex Biotherapeutics in a research report on Wednesday, October 28th. They set a “buy” rating for the company. Wall Street Zen cut Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Finally, Weiss Ratings raised Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold”.
View Our Latest Analysis on LABT
About Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
See Also
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
